to the editor: Bone resorption and bone formation are coupled, and alendronate, which decreases bone turnover, impairs the anabolic effect of para- Parathyroid hormone-mediated decreases in forearm bone mineral density are due to increases in bone area. 2 Bisphosphonates reduce the risk of hip fractures. It is unknown whether parathyroid hormone reduces the risk of hip fractures. The clinical meaning of the inhibition of parathyroid hormonemediated increases in bone-formation markers by alendronate is also unknown. Markers of bone formation reflect osteoblast activity, not necessarily bone formation. 3 Additional evidence that we do not understand the meaning of the biomarker changes is the observation made by Finkelstein et al. that after 12 months of parathyroid hormone administration, levels of bone-formation markers decline, yet bone mineral density continues to improve. It is too soon to make judgments about parathyroid hormone-bisphosphonate combinations from the available data. dr. black and colleagues reply: Dr. Miller makes some interesting points regarding our study of parathyroid hormone and alendronate, although we certainly do not suggest in our article that combination therapy with parathyroid hormone and bisphosphonate is a bad idea. In fact, we discuss virtually all the limitations mentioned by Dr. Miller. As he states, combination therapy does increase bone mineral density, and this increase was more evident in the two-year study by Finkelstein et al. than in our oneyear study. However, we hypothesized that the combination would have an additive or synergistic effect, and in neither study was there evidence that the combination was superior to the better of the two agents given alone. There is obviously a great need for more data with regard both to recombinant human parathyroid hormone (1-34) (teriparatide), which was used by Finkelstein et al., and to the fulllength molecule, recombinant human parathyroid hormone (1-84), which we used. However, the results of these two studies, along with data presented at the September 2003 meeting of the American Society for Bone and Mineral Research, suggest that parathyroid hormone (1-84) and parathyroid hormone (1-34) interact with alendronate in similar ways. As we discuss in our article, the results with alendronate cannot necessarily be generalized to combination therapy with other bisphosphonates or other antiresorptive drugs. The implications of quantitative CT and biochemical-marker end points with respect to bone strength and the risk of fracture are not entirely clear, and final judgment awaits more definitive trials. However, with that caveat, we believe that the data that are currently available support the notion that responses to parathyroid hormone therapy are maximized when bone turnover is not being suppressed during the course of treatment.
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In response to Dr. Sugiyama and colleagues: Although our study did not provide evidence of a synergistic effect of parathyroid hormone and alendronate, it is entirely possible that other combinations of anabolic and antiresorptive agents would have other results. In addition, other combinations, including combinations with vitamin K, might be useful to study.
In response to Dr. Vegni and colleagues: Osteoprotegerin is a potentially useful surrogate marker that might provide distinct information. We agree that it should be included in future studies.
In response to Dr. Fuller: Our patients had sufficient vitamin D levels, according to measurements made at base line. Because their dietary intake of vitamin D was supplemented with 400 IU daily (as recommended by the Food and Drug Administration), it is highly unlikely that our patients became vitamin D-deficient during the study. We agree that this nutrient is important in therapeutic regimens for osteoporosis. We look forward to seeing analyses (from our own study and others) of the effect of base-line vitamin D levels on the effect of parathyroid hormone. Dennis M. Black, Ph.D. Dr. Miller notes that we did not use the currently approved formulation of recombinant human parathyroid hormone . Our formulation of human parathyroid hormone (1-34), made by solidphase synthesis, is identical to the recombinant molecule and produces results indistinguishable from those obtained with the recombinant molecule in animals and humans. Dr. Miller also notes that we did not report the incidence of fracture and cannot be certain how the observed changes in bone density and bone turnover will affect the risk of fracture. For that reason, we were careful to state in our conclusions that "additional studies are needed before combinations of antiresorptive agents and parathyroid hormone can be recommended for the treatment of men with osteoporosis." As Dr. Miller notes, combination therapy was associated with an impressive increase in spinal bone mineral density. Parathyroid hormone monotherapy was even better, however. In laboratory animals, there is a direct relationship between parathyroid hormone-induced increases in bone mineral density and resistance to fracture. Considerable evidence also demonstrates a direct relationship between increases in bone mineral density and decreases in the risk of fracture in humans. 1 Thus, until clinical trials compare the effects of parathyroid hormone alone and those of parathyroid hormone plus alendronate on the risk of fracture, it seems reasonable to treat patients with the regimen that provides greater increases in bone density, particularly because parathyroid hormone monotherapy is less expensive than combination therapy and exposes patients to a lower risk of side effects.
Dr. Fuller is concerned that only base-line levels of 25-hydroxyvitamin D are reported, and that the results might have been altered if the subjects subsequently had vitamin D deficiency. Although we did not report these data, we did measure serum 25-hydroxyvitamin D levels every six months. The mean ( ± SD) levels ranged from a low of 23 ± 8 ng per milliliter to a high of 25 ± 9 ng per milliliter in the men treated with alendronate alone, from 18 ± 5 to 27 ± 10 ng per milliliter in the men treated with parathyroid hormone alone, and from 21 ± 7 to 28 ± 12 ng per milliliter in the men treated with both. These levels did not differ significantly among the groups. 
